This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sonea, I. M.
Right arrow Articles by Harp, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sonea, I. M.
Right arrow Articles by Harp, J. A.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, March 2002, p. 333-340, Vol. 9, No. 2
1071-412X/02/$04.00+0     DOI: 10.1128/CDLI.9.2.333-340.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Treatment with Neurokinin-1 Receptor Antagonist Reduces Severity of Inflammatory Bowel Disease Induced by Cryptosporidium parvum

Ioana M. Sonea,1* Mitchell V. Palmer,2 Dhuha Akili,1 and James A. Harp2

Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, Iowa 50011,1 National Animal Disease Center, Agricultural Research Service, U.S. Department of Agriculture, Ames, Iowa 500102

Received 3 August 2001/ Returned for modification 11 October 2001/ Accepted 20 November 2001

Inflammatory bowel disease (IBD) is a chronic, debilitating disorder of uncertain and perhaps multiple etiologies. It is believed to be due in part to disregulation of the immune system. Neuroimmune interactions may be involved in induction or maintenance of IBD. In the present study, we examined the potential role of a neurotransmitter, substance P, in a mouse model of IBD. We found that binding sites for substance P, and more specifically, neurokinin-1 receptors, were upregulated in intestinal tissue of mice with IBD-like syndrome. Dosing of mice with LY303870, a neurokinin-1 receptor antagonist, reduced the severity of IBD, and treatment of mice with preexisting IBD allowed partial healing of lesions. We hypothesize that blocking the binding of substance P to the neurokinin-1 receptor interrupts the inflammatory cascade that triggers and maintains intestinal lesions of IBD.

* Corresponding author. Mailing address: Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA 50011. Phone: (515) 294-3719. Fax: (515) 294-2315. E-mail: ioana{at}iastate.edu.

Clinical and Diagnostic Laboratory Immunology, March 2002, p. 333-340, Vol. 9, No. 2
1071-412X/02/$04.00+0     DOI: 10.1128/CDLI.9.2.333-340.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»